The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

Key Takeaways The S&P 500 added 0.7% on Monday, Dec. 23, 2024, with communication and tech stocks outperforming as the ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

Chip stocks advanced, led by Broadcom ( AVGO) after UBS analysts raised their price target for the stock, citing the ...

Department store chain Nordstrom (JWN) has accepted a $6.25 billion all-cash buyout offer to end its 53-year run as a ...

The FDA approved Eli Lilly's (LLY) obesity drug for the treatment of sleep apnea, sending rival ResMed (RMD) stock lower ...

Sleep apnea can significantly increase health risks, even the risk of death, so doctors strongly recommend people address it. But standard therapy with breathing devices known as CPAPs are not hugely ...

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.

ResMed (RMD+0.34%), a seller sleep of apnea devices, said its revenue rose 11% during its fiscal year ending in June. The ...

My task today was to hunt for ASX companies that share some of those traits. Some of the points I touched on in the Monster ...

Popular weight-loss drugs like Wegovy and Zepbound are boosting the use of healthcare in the U.S., leading to an uptick in ...

The sleep screening devices market is projected to grow from US$ 9,298 million in 2023 to US$ 17,564.5 million by 2033, at a ...